SL-1002 / Saol Therap - LARVOL DELTA

Phase III Study to Assess the Safety and Efficacy of SL1002 for Osteoarthritis Knee Pain (clinicaltrials.gov) - P3 | N=150 | Recruiting | Sponsor: Saol Therapeutics Inc

New P3 trial • Immunology • Musculoskeletal Pain • Osteoarthritis • Pain • Rheumatology

Saol Therapeutics Announces Completion of Enrollment in Both the Phase II COMPASS Osteoarthritis Knee Pain Trial and the Phase II RAISE Limb Spasticity Trial (PRNewswire) - "Saol Therapeutics...announced today that enrollment has been completed in the company's two Phase II trials for SL-1002....Both the COMPASS Osteoarthritis Knee Pain Trial...and the RAISE Limb Spasticity Trial...are each fully enrolled, at 132 patients and 32 patients, respectively....Saol Therapeutics currently expects topline results for the COMPASS Osteoarthritis Knee Pain Trial in the first quarter of 2024, and the RAISE Limb Spasticity Trial in the second quarter of 2024."

Enrollment closed • P2 data • CNS Disorders • Muscle Spasticity • Osteoarthritis • Pain

Phase II Study to Assess Safety, Pharmacokinetics and Efficacy of SL-1002 for Limb Spasticity (clinicaltrials.gov) - P2 | N=32 | Active, not recruiting | Sponsor: Saol Therapeutics Inc | Recruiting ➔ Active, not recruiting

Enrollment closed • Movement Disorders

Saol 1010-01: Phase II Study to Assess Safety and Efficacy of SL-1002 for Osteoarthritic Knee Pain (clinicaltrials.gov) - P2 | N=132 | Active, not recruiting | Sponsor: Saol Therapeutics Inc | Recruiting ➔ Active, not recruiting

Enrollment closed • Immunology • Musculoskeletal Pain • Osteoarthritis • Pain • Rheumatology

Saol Therapeutics Announces First Patient Enrolled in Phase 2 COMPASS Trial Evaluating the Safety and Efficacy Profile of SL-1002 for Treatment of Knee Pain Associated with Osteoarthritis (PRNewswire) - "Saol Therapeutics...announced today that the first patient has been enrolled in the company's Phase 2 COMPASS Osteoarthritis Pain Trial....The trial is a multicenter, randomized, double-blind, placebo-controlled, single ascending-dose escalation study to assess the safety and efficacy of SL-1002 for the treatment of knee pain associated with osteoarthritis in adult patients....The first patient in the trial was enrolled at the International Spine, Pain and Performance Center in Washington, D.C....Saol Therapeutics currently expects topline results of both the COMPASS Osteoarthritis Pain Trial...in 2023."

Enrollment open • P2 data • CNS Disorders • Osteoarthritis • Pain

Saol 1010-01: Phase II Study to Assess Safety and Efficacy of SL-1002 for Osteoarthritic Knee Pain (clinicaltrials.gov) - P2 | N=132 | Recruiting | Sponsor: Saol Therapeutics Inc

New P2 trial • Immunology • Musculoskeletal Pain • Osteoarthritis • Pain • Rheumatology

Phase II Study to Assess Safety, Pharmacokinetics and Efficacy of SL-1002 for Limb Spasticity (clinicaltrials.gov) - P2 | N=32 | Recruiting | Sponsor: Saol Therapeutics Inc | Not yet recruiting ➔ Recruiting

Enrollment open • Movement Disorders

Saol Therapeutics Announces First Patient Dosed in Phase 2 RAISE Spasticity Trial Evaluating the Safety Profile of SL-1002 for Limb Spasticity (PRNewswire) - "...Saol Therapeutics also announced a second open IND for SL-1002 for the treatment of pain related to osteoarthritis of the knee. The first patient in that trial – the COMPASS Osteoarthritis Trial – is expected to be dosed in Q2, 2022....Saol Therapeutics currently expects topline results of...the COMPASS Osteoarthritis Trial to readout in the first half of 2023."

Clinical data • IND • Trial status • CNS Disorders • Osteoarthritis • Pain

Phase II Study to Assess Safety, Pharmacokinetics and Efficacy of SL-1002 for Limb Spasticity (clinicaltrials.gov) - P2 | N=32 | Not yet recruiting | Sponsor: Saol Therapeutics Inc

New P2 trial • Movement Disorders